White label – Pompe disease - ClinicalTrials.eu

Study on the Safety and Effects of Givinostat in Young Children with Duchenne Muscular Dystrophy (Ages 2 to Less Than 6 Years)

Recruiting

2 1 1
Investigated Diseases:
- Duchenne muscular dystrophy
Investigated Drugs:
- Givinostat
Study of dabrafenib and trametinib combination therapy before and after surgery in patients with BRAF-mutated anaplastic thyroid cancer

Recruiting

2 1 1 1
Investigated Drugs:
- Dabrafenib
- Trametinib
Study on Ruxolitinib for Treating Inclusion Body Myositis in Patients

Recruiting

2 1 1
Investigated Diseases:
- Inclusion body myositis
Investigated Drugs:
- Ruxolitinib
Study of LY3537982 for Patients with Advanced Solid Tumors with KRAS G12C Mutation

Recruiting

2 1 1 1
Investigated Drugs:
Study of Axitinib and Etoposide for Children and Young Adults with Refractory or Relapsing Medulloblastoma and Ependymoma

Recruiting

1 1 1 1
Investigated Diseases:
- Ependymoma malignant
- Medulloblastoma recurrent
Investigated Drugs:
- Axitinib
- Etoposide
Study on VE303 for Preventing Recurrent C. difficile Infection in Patients

Recruiting

3 1
Investigated Diseases:
- Clostridium difficile infection
Investigated Drugs:
+8
Long-Term Safety and Efficacy Study of Mexiletine Hydrochloride for Patients with Myotonic Dystrophy Type 1 and Type 2

Recruiting

3 1 1
Investigated Drugs:
- Mexiletine Hydrochloride
Study of Cemiplimab, Carboplatin, and Paclitaxel for Adults with Operable Non-Small Cell Lung Cancer

Recruiting

2 1 1 1
Investigated Diseases:
- Non-small cell lung cancer
Investigated Drugs:
Study on the Effects of Landiolol Hydrochloride for Patients with Microcirculatory Issues During Septic Shock

Recruiting

3 1 1 1
Investigated Drugs:
- Landiolol Hydrochloride
Study on the Safety and Effectiveness of Navtemadlin and Ruxolitinib for Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Recruiting

1 1 1 1
Investigated Diseases:
- Myelofibrosis
- Primary myelofibrosis
Investigated Drugs:
- Navtemadlin
- Ruxolitinib

Full Name *

e-Mail *

Country Prefix *

Phone Number *

Nationality *

Gender *

Check all consents

Check all consents

I accept the Terms and Conditions and Privacy Policy *

*I accept the Terms and Conditions and Privacy Policy

I consent to receiving commercial information from the Service Operator *

*I consent to receiving commercial information from the Service Operator

I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes *

*I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes

We use cookies